Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. [electronic resource]
Producer: 20191230Description: 4 p. digitalISSN:- 2044-5385
- Animals
- Antineoplastic Agents -- pharmacology
- Binding Sites
- Biomarkers, Tumor
- Cell Line, Tumor
- Disease Models, Animal
- Drug Synergism
- Female
- Humans
- Indoles -- pharmacology
- Leukemia, Myeloid, Acute -- drug therapy
- Myeloid Cell Leukemia Sequence 1 Protein -- antagonists & inhibitors
- Neoplastic Stem Cells -- drug effects
- Protein Binding
- Protein Kinase Inhibitors -- pharmacology
- Proteins -- antagonists & inhibitors
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Pyridones -- pharmacology
- Sulfonamides -- pharmacology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.